Calcipotriene

ANDA 77029, held by Chartwell Rx. Calcipotriene.

As of Nov 15, 2026, ANDA 77029 (Calcipotriene), held by Chartwell Rx, was first approved by FDA on Nov 20, 2009, with 1 approved supplement and 0 published complete response letters.

First approved: Nov 20, 2009
Supplements approved: 1
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 2 submissions below

Date	Submission	Status	Documents
Nov 20, 2009	Original application	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Calcipotriene0.005% · solution;topical	Calcipotriene	Discontinued

All 2 submissions, including labeling and manufacturing supplements


Nov 30, 2012	Supplement 9Labeling · Standard review	Approved	None posted
Nov 20, 2009	Original application	Approved	None posted

Identifiers

Application: ANDA 77029
Drugs@FDA: Overview at FDA
Company: Chartwell RX

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters